7 results match your criteria: "and the German Center for Infection Research[Affiliation]"
Ceftobiprole for Treatment of Complicated Bacteremia.
N Engl J Med
October 2023
From the Division of Infectious Diseases, Duke University (T.L.H., N.A.T., V.G.F.), and Duke Clinical Research Institute (T.L.H., V.G.F.) - both in Durham, NC; the Department of Medicine, Johns Hopkins University School of Medicine, Baltimore (S.E.C.); the Division of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco (S.B.D.); the Division of Infectious Diseases, Department of Medicine, Denver Health, Denver (T.C.J.); Tufts Medicine and Tufts University School of Medicine, Boston (H.W.B.); Zaycev V.T. Institute of General and Emergency Surgery of the National Academy of Medical Sciences of Ukraine, Kharkiv (O.P.), Regional Clinical Hospital, Ivano-Frankivsk Regional Council, Ivano-Frankivsk (I.T.), and Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital, Dnipro (S.K.) - all in Ukraine; Eurohospital Plovdiv, Plovdiv (B.A.), and University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov," Clinic of Purulent-Septic Surgery, Sofia (I.P.) - both in Bulgaria; LTD Academician Vakhtang Bochorishvili Clinic, Tbilisi, Georgia (M.M.); N.I. Pirogov City Clinical Hospital No. 1, Moscow (A.A.); the Department of Medicine and Division of Infectious Diseases, Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires (M.E.S.); Basilea Pharmaceutica International, Allschwil, Switzerland (M.A.G., M.E., K.H., D.I., M.J., M.S., J.S.); and the Institute for Medical Microbiology, Immunology, and Hygiene, Medical Faculty and University Hospital Cologne, University of Cologne, and the German Center for Infection Research, Partner Site Bonn-Cologne - both in Cologne, Germany (H.S.).
Background: Ceftobiprole is a cephalosporin that may be effective for treating complicated bacteremia, including methicillin-resistant .
Methods: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators). The primary outcome, overall treatment success 70 days after randomization (defined as survival, bacteremia clearance, symptom improvement, no new bacteremia-related complications, and no receipt of other potentially effective antibiotics), with a noninferiority margin of 15%, was adjudicated by a data review committee whose members were unaware of the trial-group assignments.
Mass cytometry-based identification of a unique T-cell signature in childhood allergic asthma.
Allergy
January 2022
Institute for Medical Microbiology and Hospital Hygiene, Philipps-University Marburg, Marburg, Germany.
Aiming for zero tuberculosis transmission in low-burden countries.
Lancet Respir Med
November 2017
National Institutes of Health Research Oxford Biomedical Research Centre, University of Oxford and the Department of Microbiology and Infectious Disease, Oxford University Hospitals National Health Service (NHS) Trust, Oxford, UK; National Infection Service, Public Health England, London, UK.
Increased peripheral CD4 regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.
J Hepatol
May 2017
Department of Internal Medicine I, University of Bonn, Bonn, Germany, and the German Center for Infection Research (DZIF), Partner Site Cologne-Bonn, Bonn, Germany.
Background & Aims: CD4 regulatory T cells (Tregs) expand during chronic hepatitis C virus (HCV) infection, inhibit antiviral immunity and promote fibrosis. Direct-acting antiviral agents (DAA) have revolutionized HCV therapy. However, it is unclear if Tregs are normalized after DAA-induced HCV elimination.
View Article and Find Full Text PDFBroadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.
N Engl J Med
November 2016
From the Laboratory of Molecular Immunology (M.C., M.C.N.) and the Howard Hughes Medical Institute (M.C.N.), Rockefeller University, New York; and the Laboratory of Experimental Immunology, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, and the German Center for Infection Research, partner site Bonn-Cologne - all in Cologne, Germany (F.K.).
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
N Engl J Med
April 2016
From the Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon (S.T.A., J.F.F., A.A.A., E.B.B., J.S.B., M.P.G., A.L.K., B. Lell, M.M.-L., B.M., M.R., S.K., P.G.K.); Institut für Tropenmedizin, Universitätsklinikum Tübingen, and German Center for Infection Research, Tübingen (S.T.A., J.F.F., A.A.A., E.B.B., J.S.B., M.P.G., A.L.K., B. Lell, M.M.-L., B.M., M.R., S.K., P.G.K.), University Medical Center Hamburg-Eppendorf, 1st Department of Medicine (M.E.Z., C.D., R.K., A.W.L., A.N., S.S., H.C.S., M.M.A.), and Institute for Clinical Chemistry and Laboratory Medicine (F.R.S.), German Center for Infection Research, partner site Standort Hamburg-Lübeck-Borstel (C.D., A.N., J.S.-C., H.C.S., M.M.A.), Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology (M.A.), Clinical Trial Center North (S. Borregaard, A.J.), and Bernhard Nocht Institute for Tropical Medicine, World Health Organization (WHO) Collaborating Center for Arbovirus and Hemorrhagic Fever Reference and Research, National Reference Center for Tropical Infectious Diseases (J.S.-C.), Hamburg, Philipps University Marburg, Institute for Virology, and the German Center for Infection Research (DZIF), partner site Giessen-Marburg-Langen, Marburg (V.K., N.B., M.E., S.K.F., T.S., S. Becker), and the Division of Veterinary Medicine, Paul Ehrlich Institute, Langen (R.K.) - all in Germany; the Infection Control Program (A.H.), Divisions of Infectious Diseases (A.H., J.-A.D., L.K.), Clinical Epidemiology (C.C.), Rheumatology (A.F.), and Dermatology (G.K.), and Centers for Clinical Research (J.D., A.M.) and Vaccinology (C.-A.S.), Geneva University Hospitals and Faculty of Medicine, the Virology Laboratory, Geneva University Hospitals (S.Y., A.R.G., L.K.), WHO Collaborative Center for Vaccinology, Faculty of Medicine (F.A., B. Lemaître, C.-A.S.), and the WHO (P.F., V.M., M.-P.K.) - all in Geneva; the Kenya Medical Research Institute-Wellcome Trust Research Program, Center for Geographic Medicine
Background: The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.
Methods: We performed three open-label, dose-escalation phase 1 trials and one randomized, double-blind, controlled phase 1 trial to assess the safety, side-effect profile, and immunogenicity of rVSV-ZEBOV at various doses in 158 healthy adults in Europe and Africa. All participants were injected with doses of vaccine ranging from 300,000 to 50 million plaque-forming units (PFU) or placebo.
Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.
Viruses
November 2014
FAS Center for Systems Biology, Harvard University, Cambridge, MA 02138, USA.
In 2014, Ebola virus (EBOV) was identified as the etiological agent of a large and still expanding outbreak of Ebola virus disease (EVD) in West Africa and a much more confined EVD outbreak in Middle Africa. Epidemiological and evolutionary analyses confirmed that all cases of both outbreaks are connected to a single introduction each of EBOV into human populations and that both outbreaks are not directly connected. Coding-complete genomic sequence analyses of isolates revealed that the two outbreaks were caused by two novel EBOV variants, and initial clinical observations suggest that neither of them should be considered strains.
View Article and Find Full Text PDF